tag:blogger.com,1999:blog-908170965222939769.post8881550928174927784..comments2024-03-21T00:26:27.529-07:00Comments on Cancer....an unexpected journey.: New England Journal of Medicine: ROS1 Mutations and Crizotinib (Xalkori) - Phase 1 DataLuna O.http://www.blogger.com/profile/14260979903110837686noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-908170965222939769.post-35577701040129809492014-10-07T19:28:27.126-07:002014-10-07T19:28:27.126-07:00Thanks for the clarification. Between you and Tor...Thanks for the clarification. Between you and Tori, I think I have it straight now. I'm not sure what I've been reading and how I misunderstood the details. I didn't realize Xalkori for ROS1 was an off-label use. <br />Luna O.https://www.blogger.com/profile/14260979903110837686noreply@blogger.comtag:blogger.com,1999:blog-908170965222939769.post-10898538694280018562014-10-07T15:07:19.032-07:002014-10-07T15:07:19.032-07:00Luna,
A bit of clarification:
Xalkori has not b...Luna,<br /><br />A bit of clarification: <br />Xalkori has not been fast-tracked for ROS1-positive lung cancer--Pfizer, the drug's manufacturer, hasn't applied to the FDA for any approvals of Xalkori related to ROS1.<br /><br />However, Xalkori IS an FDA-approved drug for ALK-positive non-small cell lung cancer, and a previous journal article showed Xalkori produced amazingly good preliminary response in ROS1-positive NSCLC patients. So, oncologists are prescribing Xalkori for ROS1 "off label," and most insurance plans are covering it.Anonymousnoreply@blogger.com